Approximately 15% to 20% of patients with breast cancer have HER2-positive disease. Brain metastases are relatively common in patients with HER2-positive metastatic breast cancer, with up to 50% of patients developing metastases over time. The American Society of Clinical Oncology (ASCO) recently
issued an updated guideline for the management of brain metastases in patients with HER2-positive breast cancer (Ramakrishna N, et al. J Clin Oncol. 2014;32:2100-2108).
The main recommendations from ASCO are:
The original panel and another group of experts subjected the draft recommendations to 2 rounds of formal ratings before approval.